Platform for brain network sensing and stimulation with quantitative behavioral tracking: Application to limbic circuit epilepsy

Authors: Vaclav Kremen[1,2]*, Vladimir Sladky[1,3]*, Filip Mivalt[1,4]*, Nicholas M. Gregg[1], Irena Balzekas[1,5], Victoria Marks[1,5], Benjamin H. Brinkmann[1,5], Brian Nils Lundstrom[1], Jie Cui[1], Erik K. St Louis[6], Paul Croarkin[7], Eva C Alden[7], Julie Fields[7], Karla Crockett[1], Jindrich Adolf[4], Jordan Bilderbeek[5], Dora Hermes[5], Steven Messina[8], Kai J. Miller[9], Jamie Van Gompel[9], Timothy Denison[10], Gregory A. Worrell[1,5]

[1]Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905
[2]Czech Institute of Informatics, Robotics, and Cybernetics, Czech Technical University, 16000 Prague, Czech Republic,
[3]Faculty of Biomedical Engineering, Czech Technical University, 16000 Prague, Czech Republic,
[4]Department of Biomedical Engineering, Faculty of Electrical Engineering and Communication, Brno University of Technology, 61600 Brno, Czech Republic.
[5]Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota 55905,
[6]Center for Sleep Medicine, Departments of Neurology and Medicine, Divisions of Sleep Neurology and Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905
[7]Departments of Psychiatry and Psychology
[8]Department of Radiology, Mayo Clinic Rochester, Minnesota 55905
[9]Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota 55905
[10]Department of Engineering Science, Medical Research Council Brain Network Dynamics Unit, University of Oxford, Oxford OX3 7DQ, United Kingdom

Abstract (218 words)
Temporal lobe epilepsy (TLE) is a common neurological disease characterized by recurrent focal seizures. These seizures often originate from the mesial temporal limbic networks and the parahippocampal neocortex. People with TLE frequently experience comorbidities related to memory, mood, and sleep (MMS). Deep brain stimulation targeting the anterior nucleus of the thalamus (ANT-DBS) is a proven therapy for reducing TLE seizures, but the optimal stimulation parameters for improving seizures and MMS comorbidities remains unclear. We developed a neurotechnology platform for tracking seizures and MMS during ANT-DBS to address this clinical gap. The platform enables bidirectional data streaming between a brain sensing-stimulation implant, compact mobile devices, and cloud-based data storage, viewing, and computing environment. Machine learning algorithms provided accurate, unbiased catalogs of seizures, interictal epileptiform spikes (IES), and wake-sleep brain states to inform ANT-DBS. Remotely administered memory and mood assessments were used to objectively and densely sample cognitive and behavioral response to ANT-DBS. In participants with mesial TLE, we evaluated the efficacy of low-frequency versus high-frequency ANT-DBS. Low-frequency and high-frequency ANT-DBS both reduced reported seizures. But continuous low-frequency ANT-DBS showed greater reductions in electrographic seizures and IES, as well as better sleep and verbal memory compared to high-frequency ANT-DBS. These results highlight the potential of synchronized brain sensing and behavioral tracking for optimizing neuromodulation therapies.

Introduction (765 words)

Epilepsy is a common neurologic disease characterized by recurrent seizures and affects over 50 million people worldwide[1,2]. In addition to seizures, the quality of life for people with epilepsy (PWE) can be markedly affected by psychiatric and neurologic comorbidities[3]. Epilepsy is a network circuit disorder with dysregulation of specific brain networks underlying the sporadic seizures and chronic comorbidites[3–5]. Anti-seizure medications are the mainstay of epilepsy therapy, but over 1/3 of PWE are drug resistant[6] and continue to have seizures despite taking daily medications.

Mesial temporal lobe epilepsy (mTLE) is one of the most common epilepsies and is defined by focal seizures originating from limbic circuits[7,8] involving amygdala, hippocampus (HPC) and parahippocampal neocortex. mTLE is frequently drug resistant and mood, memory, and sleep (MMS) disturbances[9,10] are common given the limbic circuit origin. Resective or ablative surgical procedures targeting mesial temporal structures are proven treatments for drug resistant mTLE[10,11]. Many PWE and mTLE, however are not good surgical candidates because destruction of the circuits responsible for their seizures will negatively impact memory[10,12]. Since the same limbic circuitry responsible for mTLE continues to perform vital cognitive function and emotional regulation when it is not producing sporadic, disabling seizures. People with normal structural imaging[12], bilateral mTLE, or high baseline memory performance pose challenges for safe and effective surgery, inspiring interest and need for non-destructive, reversible therapeutic approaches such as electrical brain stimulation.[13]

Deep brain electrical stimulation targeting the anterior nucleus of the thalamus (ANT-DBS) is a proven therapy for focal epilepsy[14,15]. The pivotal SANTE trial was a landmark multi-center, placebo-controlled, double blinded clinical trial that showed duty cycle, high-frequency (145 Hz; 1 minute on and 5 minutes off) ANT-DBS reduced seizures. Most patients (66%) in the SANTE trial had TLE. The use of high-frequency (HF-ANT) stimulation was motivated by animal research showing it increased seizure threshold[16,17,18] and disrupted seizure propagation[13,19]

The blinded SANTE trial phase demonstrated a median seizure reduction from baseline of 40.4% in the active stimulation group and 14.5% in the control non-stimulation group ($p < 0.05$). In the subsequent open-label phase the median seizure frequency reduction reached 69%, and 16% of participants had at least one 6-month seizure-free period over the 5-year open label phase[15]. Given the ANT[20,21] is an important limbic network node[8], it is also important to consider the impact of ANT-DBS on mood, memory, and sleep (MMS) comorbidities. In the SANTE trial, participants receiving HF-ANT reported depressive mood (14.8% vs. 1.8%) and memory impairment (13.0% vs. 1.8%) symptoms more frequently than the non-stimulated control group[14]. However, standard neuropsychological assessments did not detect measurable objective changes [22]. The effect of ANT-DBS on sleep has received less attention, but it is known HF-ANT can disrupt sleep[23–25].

These results highlight the importance of quantitatively tracking seizures and MMS comorbidities during ANT-DBS. Seizure detection is limited on current DBS devices with brain sensing[26–28]. Without accurate seizure catalogs and appropriately dense behavioral tracking of MMS comorbidities, optimizing neuromodulation therapy will remain challenging. Relatively little is known about ANT-DBS parameter optimization[29,30]. The assessment of MMS has primarily relied on sparse data collected at clinic visits. Furthermore, even with the

development of ANT-DBS sensing devices that record intracranial local field potentials (LFPs), studies have continued to rely on patient diaries that are known to be inaccurate[31–34]. In addition, whether HF-ANT or alternative stimulation paradigms for mTLE are optimal for seizure reduction and MMS comorbidities remains unknown. In particular, continuous low-frequency stimulation targeting limbic network nodes has shown promising seizure suppressing effects in rodent[35–39] models and in humans[40,41]. In human mTLE, both low-frequency[42] and high-frequency[43] stimulation targeting the HPC were effective.

Inaccurate seizure diaries and inadequate sampling of common MMS comorbidities remain fundamental gaps in clinical epileptology.   Informed by our previous studies in humans and canines with epilepsy[34,44–46] and motivated to advance the collection of continuous ecologically realistic data we sought to overcome the clinical and technology gaps discussed above by developing a neurotechnology platform enabling the creation of accurate catalogs of seizures, IES, and MMS comorbidities. The BrainRISE (Restoration and Intelligent Stimulation Ecosystem) platform enables bi-directional connectivity between an implanted sensing-stimulation device, local mobile devices, and cloud computing environment using wireless cellular and internet protocols. Remote assessments of mood, memory and sleep are synchronized with limbic network LFPs and ANT-DBS. Machine learning algorithms create accurate catalogs of seizures, IES, and wake-sleep brain states. A phase I clinical study in five people with mTLE evaluated safety and feasibility of ANT-DBS and continuous ANT and HPC sensing, two critical limbic circuit nodes, while tracking seizures, memory, mood, and sleep.

Results
Participants and Protocol
Seven people with drug-resistant mesial temporal lobe epilepsy were enrolled under FDA IDE: G180224 and Mayo Clinic IRB: 18-005483 *Human Safety and Feasibility Study of Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy* https://clinicaltrials.gov/ct2/show/NCT03946618. All 7 participants had co-morbid depression, anxiety, and sleep disturbances (insomnia, hypersomnolence). Participants had comprehensive Phase-I non-invasive evaluations for their drug resistant epilepsy including MRI, DTI, functional imaging, and multi-day video scalp EEG to record their habitual seizures. Three participants had invasive intracranial stereo-EEG (Table 1). Six participants met the inclusion criteria with at least 3 reported disabling seizures per month at baseline using the tablet computer proprietary application to create an electronic diary of reported seizures. One participant declined further participation after the baseline data collection, and five participants were implanted with the investigational neural sensing-stimulation device (Figure 1, and supplementary material).

Figure 1 near here
Table 1 near here

The primary study outcome measures were: **1)** Device-related adverse events (AE) with investigational 4-lead Medtronic Summit RC+S™ system (RC+S™) integrated with off-the-body local and cloud computing. The goal was to show device-related AE with a 4-lead sensing and stimulation device is not significantly greater than observed in the pivotal SANTE trial that used 2-leads targeting bilateral ANT[14]. **2)** Feasibility of 24/7 continuous LFP streaming. **3)** Feasibility of creating accurate catalogs of seizures, IES, mood, memory, and wake-sleep behavioral state.

Here we also report the effect of low-frequency (LF-ANT) and high-frequency (HF-ANT) paradigms on IES, seizures, sleep, mood, and memory. The development of precise, comprehensive catalogs encompassing seizure events, IES, and associated neuropsychological data such as mood, memory, and wake-sleep behaviors was feasible by integrating multiple devices using wireless data streaming protocols with cloud computing infrastructure and advanced artificial intelligence (AI) methods.

Outcomes & System Related Adverse Events.
Five people with mTLE were implanted with bilateral ANT leads and bilateral amygdala-hippocampal leads. The ANT leads were used for ANT-DBS and the HPC leads were used for LFP sensing. Each implanted lead has 4 electrode contacts that can be used for sensing or electrical stimulation (Figure 1 and supplementary material). All five participants had independent left and right temporal lobe IES and seizures captured during the phase-I non-invasive evaluation. Participants M1, M3, and M4 had phase-II invasive evaluations with intracranial stereo-EEG demonstrating bilateral independent IES and seizures (Table 1).

The custom epilepsy patient assistant (EPA) application running on a tablet computer or smartphone was used by participants to report their seizures. When compared to baseline reported seizure counts the patient reported seizures were reduced with both HF-ANT and LF-ANT stimulation (Figure 2A; $p < 0.05$). The magnitude of reported seizure reduction using LF-ANT and HF-ANT paradigms was similar (-52% and -56%, $p > 0.05$).

Figure 2 near here

In the five mTLE participants implanted with the RC+S™ device comprehensive mood, quality of life, seizure severity, and neuropsychological testing during in person, face-to face visits occurred at pre-implant baseline, 3 - 6 months post-implant and at 9 - 15 months post implant. There were no significant differences across participants and timepoints for the measures of mood, quality of life, seizure severity, or with standardized neuropsychological testing (Table 2).

Four reported device related adverse events over the 15-month protocol. Participant M2 inadvertently disabled therapy using the EPA application. A subsequent EPA reversion corrected this potential operator mistake, and the cloud dashboard more clearly displayed the therapy status to the clinical team. Two participants (M1 & M4) experienced behavioral changes with anxiety, dysphoria, and sleep disturbance during trials of continuous HF-DBS (see supplementary data). In both participants the reported anxiety, dysphoria and sleep disturbance resolved with changing from continuous HF-ANT to duty cycle (1 min on & 5 min off; SANTE parameters[14]). In participant M5 the right Amygdala-Hippocampal lead tail could not be fully seated into the lead extension connector at the time of surgery, leaving only three of the four contacts recording. There were no deaths, infections, bleeding, strokes, status epilepticus or other device complications. (Table 2). All subjects had NP at baseline and during low frequency ANT-DBS and high frequency duty cycle ANT-DBS. Participant M3 there was a decrease in VPA immediate and delayed recall compared to baseline. For M5 both RAVLT and VPA immediate was reduced during high frequency ANT-DBS.

Subject M4 was hospitalized for new onset functional event. Subject M5 had three overnight hospitalizations with recurrent seizures like his baseline.

Table 2 near here

We directly compared reported seizures with detected electrographic seizures captured with automated advanced artificial intelligence (AI) methods applied to the continuous LFP recordings (Figure 2B). There was a correlation between reported seizures and electrographic seizures, with substantial variability across participants (overall R^2 = 0.1, p<0.001). However, participants variably over reported symptoms without LFP correlates, and under reported detected electrographic seizures (Figure 2B). The strongest correlation between electrographic LFP detected seizures and subject reporting was found in participant M4 (R^2 = 0.62, p<0.001), in contrast with absence of any clear correlation in participant M5 (R^2 = 0.13, p>0.05). It is noteworthy that although participant M4 exhibited amnesia for her focal impaired awareness seizures (FIAS), her spouse was able to accurately log these episodes, as detailed in the supplementary data discussion. This observation was made possible due to the increased opportunities for observation during the work-from-home arrangements necessitated by the Covid-19 lockdown period.

BrainRISE Platform Performance
The BrainRISE (Restoration and Intelligent Stimulation Ecosystem) platform enables bi-directional connectivity between an implanted sensing-stimulation device, local handheld computer, mobile phone, and cloud computing environment using wireless cellular and internet protocols[44]. The connectivity between devices is orchestrated with a custom software application (Epilepsy Patient Assistant: EPA) operating on a small handheld computer carried by the participant[47]. The system uses U-band and Bluetooth wireless protocols to maintain connectivity between the multiple wireless capable devices and cloud computing environment (see supplementary material). The platform enables connection of wearable devices to collect rich behavioral data and orchestrate responsive remote questionnaires launched based on the detections or events in LFP data.

Continuous HPC sensing and LFP streaming provides the input signal for validated automated machine learning classifiers to create accurate catalogs of seizures, IES[34,48] and sleep-wake behavioral state[45,46,49] (see supplementary material).

Participants kept three devices charged to wirelessly stream LFP data: 1) RC+S™ neural sensing and electrical stimulation implanted devices; 2) Telemetry antennae; 3) handheld tablet computers. The ability to manage the 3 devices varied across participants. On average, we recorded 99.2±43.0 weeks of data for each patient during ANT-DBS. Despite technical challenges, the average performance for bidirectional streaming data flow was as high as 13.84 hrs per day. Participants captured an average of 162 ± 158 seizures over the course of the study, with variable discrepancies between patient reported seizures and reports with LFP correlates (Figure 2B and Table 3).

Table 3 near here

Circadian Patterns of Seizures and Interictal Epileptiform Spikes
All patients had seizures start unilaterally and then propagate to contralateral AMG - HPC. All participants had bilateral independent IES and all but M4 had bilateral independent seizures recorded. In all participants the IES activity was increased in left compared to right AMG-

HPC. Similarly, M1, M2, M4 and M5 had more seizures originating from the left AMG and HPC. (Table 4).

Characterization of long-term LFP recordings showed that electrographic seizures and IES occurred with greater frequency in the left HPC in each of the 5 participants with mTLE (Table 4). All participants had day-night patterns, with IES maximal at night during sleep, while seizures occurred maximally during the day during wakefulness (Figure 3). The seizures captured from continuous LFP recordings demonstrated a strong diurnal pattern with the majority of seizures occurring during the daytime (823 seizures during wakefulness vs. 113 seizures during sleep ($p<0.0001$). The timing of the daytime seizures was patient specific, with M4 showing a tendency for seizures at 2:30 PM ± 1 hr., two participants (M1, M3) with seizures preferentially occurring in the morning and evening, M2 with late afternoon and evening seizures, and M5 with more uniform distribution of seizures over the day.

The pattern of IES over a 24-hr period is distinctly different from seizures. IES are increased during sleep compared to wake for all participants ($p<0.0001$) when seizures are less likely to occur. (Figure 3B&C and see supplementary material).

Figure 3 near here
Table 4 near here

Impact of ANT-DBS on Detected Seizures and IES
The number of reported seizures decreased with ANT-DBS when compared to baseline prior to implant for both duty cycle high frequency (HF-ANT) and continuous low frequency (LF-ANT) paradigms (Figure 2A). The data from streaming LFP detected seizures, however, showed that LF-ANT reduced seizures more than HF-ANT ($p < 0.05$). Furthermore, LF-ANT significantly reduced IES compared to HF-ANT during both sleep and wakefulness ($p < 0.01$) (Figure 4). HF-ANT and LF-ANT seizure reduction during sleep was no different between active stimulation periods and baseline, but the number of seizures during sleep were small ($p > 0.05$).

Figure 4 near here

Impact of ANT-DBS on Sleep
The LFP recordings from the five participants were used as input to a validated, individualized, automated Naive Bayes sleep-wake state classifier[45] (see methods and supplementary data). As participants slept ad libitum on their own preferred sleep-wake schedules, characteristics of sleep varied widely with a range of individual features for sleep onset, offset, and duration. The number of NREM-REM cycles demonstrated substantial intraindividual and interindividual variability (Table 5). On average, across all participants the total sleep duration was 8 hrs 33 minutes, with 4.04 NREM-REM cycles and 19.9 min NREM epoch duration.

Table 5 near here.

ANT-DBS neuromodulation with continuous LF-DBS and duty cycle HF-DBS did not impact total sleep duration (sleep offset – onset), but the time spent awake after sleep onset (WASO) was reduced by LF-DBS compared to baseline without stimulation ($p < 0.05$). In contrast, duty-cycle HF-DBS increased WASO compared to baseline and LF-DBS ($p < 0.001$). Duty-

cycle HF-DBS decreased the overall time spent in NREM and REM compared to baseline without stimulation and LF-DBS. The total NREM-REM time in sleep with continuous LF-DBS neuromodulation was indistinguishable from no stimulation baseline and longer than duty-cycle SANTE HF-DBS (p < 0.05). (Figure 5 & supplementary materials).

Figure 5 near here

Impact of ANT-DBS on Memory (Ambulatory Free Recall Task)
Subjects used the epilepsy patient assistant (EPA) application on hand-held tablet computer to remotely perform a validated word-free recall task[50–53] in their natural home environments (Figure 6A). The task was performed with the subject at different times of the subject's preference (hour, day of week) over multiple months and during the two ANT-DBS stimulation paradigms. The ambulatory free-recall verbal memory task was not functional on the EPA system until after the time of implant and no pre-implant baseline data were captured. However, all 5 subjects participated after implantation and the free-recall memory task scores were better during LF-DBS compared to duty cycle HF-DBS (Fig. 6B) (See supplementary data)*.

Figure 6 near here

Impact of ANT-DBS on Mood
 All participants completed repeated assessments of mood (Beck Depression Index), suicidality (Columbia Suicide), and were also prompted at random times of the day to complete the Immediate Mood Scaler 12 (IMS)[54] deployed on the EPA application to track mood and anxiety symptoms instantaneously (see supplementary). There were no differences detected between HF-DBS and LF-DBS for mood and anxiety symptom variables. Symptoms of depression and anxiety were present in all five participants. Suicidal ideation was present in 2 participants (see supplementary material).

Discussion
Epilepsy is a complex and heterogenous disorder with multiple etiologies. Here we selected people with drug resistant mTLE to focus our investigation on limbic network circuits generating disabling seizures and MMS comorbidities. We created a unique ecosystem of implantable, wearable devices and cloud infrastructure using advanced AI methods to investigate the impact of ANT-DBS therapy on seizures and MMS in five people living with mTLE. Synchronized data[55] from multiple devices (brain sensing-stimulation implanted device, handheld computing and wearable devices) was streamed to a cloud-based data storage, viewing, and computing environment. Validated machine learning classifiers were applied to streaming hippocampal LFP recordings to create accurate catalogs of seizures, IES, and wake-sleep behavioral state. Subjects reported seizures, and remotely performed a free recall memory task and mood questionnaires using custom EPA mobile application.

The study demonstrates the feasibility and potential clinical utility of continuous tracking of brain electrophysiology and behavior in people with epilepsy living in their natural home environments (Figure 1). We characterized the circadian patterns of seizures and IES and show that seizures occur primarily during the day while awake, but IES are increased during sleep in mTLE. The mechanism(s) underlying this discordance of behavioral state dependent occurrence of IES and seizures, two fundamental measures of pathological brain excitability, remains unclear, and state-dependent modulation of cortical excitability remains a

fundamental open question and potential therapeutic opportunity. We speculate that thalamo-hippocampal circuits and state-dependent large scale and local circuit neuronal ensemble behaviors interact to modulate the local activation, spread and network propagation of pathological hippocampal electrographic activity, the net combined effects rendering seizures less frequent during non-rapid eye movement sleep than wakefulness.

Indeed, we quantify the effects of ANT-DBS on HPC seizures and show that continuous LF-ANT is as effective as the FDA approved duty cycle HF-ANT stimulation paradigm for reducing patient reported seizures. But importantly, LF-ANT stimulation showed greater reductions in electrographic seizures and IES, objective biomarkers of pathologic network excitability[56,57], in both wakefulness and sleep, and resulted in better objective measures of sleep and verbal memory than did HF-ANT (Figures 2, 4- 6).

HF-ANT is proven to reduce seizures, but there may be more optimal stimulation paradigms depending on the circuits and etiologies underlying the epilepsy, seizures, and comorbidities. Here we show that in a small number of well characterized mTLE participants having seizures generated from hippocampus, LF-ANT was more effective in reducing epileptiform activity and was better for sleep and memory than HF-ANT. The clinical relevance of reducing IES has long been debated, but recent studies have shown a deleterious impact of IES on memory[58–61] and sleep[62]. Furthermore, the role of IES on progression and maintenance of epilepsy remains poorly understood, but IES in slow-wave sleep may play a role in consolidation of epilepsy engrams and epileptogensis[63,64]. It is important to note that participants receiving ANT-DBS, both LF-ANT and HF-ANT, over multiple months did not show any evidence for possible kindling, since there was no evidence for IES or seizures increasing over time in our participants[65].

The BrainRISE platform used in the current study should prove useful for future investigations on brain stimulation optimization, targeting not only seizures but IES and related epilepsy comorbidities. Future studies will investigate adaptive and responsive electrical stimulation paradigms targeting multiple limbic network nodes in both thalamus and hippocampus. This study also demonstrates proof-of-concept toward the potential for applying BrainRISE in future human studies exploring real-time brain-behavior interrelationships for sleep-wake state determination and cognition in other non-epilepsy applications (i.e., possibly in drug resistant primary central nervous system hypersomnia such as narcolepsy, cognitive and neuropsychiatric disorders).

There are several limitations in this study. 1) The trial design is focused on safety and feasibility and does not include blinding or randomization of control no stimulation and ANT-DBS therapy. Given the proven, class-I evidence for ANT-DBS we did not feel there was clinical equipoise to withhold ANT-DBS therapy for an extended period. We did not control for duration of the therapy periods, but in subgroup analysis compare equal reporting periods. 2) The existence of cycles of seizure occurrence in epilepsy[66] is now well established, and the results obtained in any trial will likely depend on the timing of therapy and data collection. We believe we have addressed this limitation to some degree with the dense long-term monitoring. 3) Similar to other studies we use patient reports of seizures to assess the outcome of ANT-DBS. There is strong evidence that many people with epilepsy can be poor reporters of their seizures. This was demonstrated in our data when comparing proven electrographic discharges with patient reports. This is a fundamental limitation in the study of epilepsy, but here this gap is partially mitigated by the unique long-term continuous LFP

sensing after device implant. 4) We have standard neuropsychological and memory testing obtained during in person visits in the clinic at baseline prior to implant and during both LF and HF ANT-DBS that did not show changes. But we were not able to obtain baseline ambulatory free-recall memory tasks because the software system was not completed prior to enrollment of participants. Therefore, we could only compare differences in memory free recall after implantation between LF-ANT and HF-ANT. 5) The BrainRISE platform provides synchronized behavior and neural activity on an unprecedented scale in ambulatory humans, but challenges remain given the participant burden associated with keeping all device component batteries charged and wireless connectivity active. 5) It remains unknown if, and to what degree, electrographic seizures detected from streaming LFP impair consciousness. This is a fundamental gap in epilepsy that we plan to address in the future with assessments that can be triggered based on electrophysiologic changes (e.g. seizure detections) in real time.[67–69]

Methods

People with drug-resistant mesial temporal lobe epilepsy were consented under FDA Investigation device exemption clinic trial: IDE G180224 and Mayo Clinic IRB: 18-005483 *Human Safety and Feasibility Study of Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy* (clinicaltrials.gov NCT03946618). Here we report the study outcome measures: 1) Adverse events experienced during the IDE. 2) Feasibility of continuous tracking of ANT and HPC local field potentials in ambulatory human participants. 3) Continuous tracking and outcomes of seizures, interictal epileptiform spikes (IES), sleep, and memory during HF-ANT and LF-ANT deep brain stimulation.

Participants. Seven participants with drug resistant mesial temporal lobe epilepsy were identified and provided written consent in accordance with IRB and FDA requirements. Six participants met the full inclusion criteria with adequate numbers of baseline seizures, and five participants were implanted with the investigational neural sensing and stimulation device (investigational Medtronic Summit RC+S™). The demographics and clinical information of the five participants implanted with the RC+S™ are provided in Table 1.

Outcome Assessments: All participants reported their seizures using a proprietary EPA application that is part of BrainRISE platform. In addition to seizure assessments, all participants underwent assessments for mood, quality of life, seizure severity, sleep and neuropsychometric testing. Outcome assessments were obtained at baseline, 3-6 months post-implant and 9-15 months post-implant. The instruments collected include:
1) Change in mood was assessed by Beck Depression Inventory II & Columbia Suicide Severity Rating Scale (C-SSRS)
2) Change in health-related quality of life (QOL) was assessed by Quality of Life in Epilepsy-31 (QOLIE-31) and SF-36 Health Survey (SF-36).
3) Seizure Severity was assessed using the Liverpool Seizure Severity Scale (LSSS), Seizure Severity Questionnaire (SSQ) Version 3 and Mayo Seizure Scale.
4) Neuropsychological Assessments included: 1) Boston Naming Test, 2) Controlled Oral Word Association Test (COWA), 3) Rey Auditory Verbal Learning Test, 4) Wechsler Memory Scale (WMS-IV) Visual Reproduction Test 5) Wechsler Memory Scale (WMS-IV) Verbal Paired Associates

In addition to the above assessments collected in person with the participant in the office we used BrainRISE platform to remotely collect dense synchronized behavioral data and brain activity from the five ambulatory participants living in their natural home environments.

BrainRISE Platform. The electrophysiology data, patient reports and verbal memory testing were collected using epilepsy patient assistant (EPA), a custom software application running on a small handheld computer enabling bidirectional communication between implanted devices with wireless connectivity and local and cloud computing resources. The EPA orchestrates connectivity between multiple wireless capable devices (implant, tablet computer, iPhone, Apple Watch) and features custom automated python algorithms for continuous analysis of long-term LFP data, control of electrical stimulation, impedance testing, LFP analysis and an interface for collecting patient interactions[44,47] (Figure 1 and supplementary data). A key aspect of this system is the application to monitoring ambulatory subjects in their natural home environment, thereby capturing more realistic and ecologically relevant data.

The RC+S[TM] implanted device analytics and electrical stimulation do not require continuous connectivity with the BrainRISE system for ANT-DBS therapy to remain active. The ANT-DBS therapy remains active as long as the implanted RC+S[TM] device battery is adequately charged. During combined ANT-DBS and continuous 4-channel LFP streaming (250 Hz sampling) the RC+S[TM] device required daily charging. At 30% battery status the LFP streaming is automatically disabled by the EPA application to maintain therapy. In this scenario with LFP streaming disabled, therapy remains active for approximately 1 week. The system also supports duty cycle LFP streaming paradigms, e.g. 10 minutes every 60 minutes, that can be used to preserve battery charge.

Investigational Medtronic Summit RC+S[TM] (supplementary data). In this study the investigational Medtronic Summit RC+S[TM] implantable device was integrated with BrainRISE platform. The investigational Medtronic Summit RC+S[TM] provides bidirectional wireless communication, programmable 16 channel electrical stimulation, and continuous 4 channel (selected bipolar pairs) wireless LFP streaming[44,70,71]. Bipolar pairs of contacts in ANT, AMG and HPC were used for sensing and streaming LFP (sampled at a frequency of 250 – 1000 Hz) to the local tablet computer running the custom EPA application. The contacts used to create lead specific bipolar recordings were selected by visual review of LFP data during seizures, resting wakefulness, and sleep-wake transitions.

Lead and Electrode Contact Localization (Figure 1B and supplementary material). Five participants (M1, 2, 3, 4, 5) had four leads stereotactically implanted into bilateral ANT and bilateral AMG-HPC. M1, 3, 4, and M5 were implanted with Medtronic 3387-lead in the ANT and Medtronic 3391 in the AMG-HPC sites. Participant M2 had a Medtronic 3387-lead implanted in the left HPC because she had previously undergone a left anterior temporal lobectomy leaving only a residual left HPC tail. Participant M5 does not have a right AMG electrode contact because the 3391-lead tail could not be fully seated into the lead extension connector at the time of surgery, leaving only 3 of the 4 contacts available for recording. For all participants 4 implanted leads (16 total electrode contacts) were localized with post-operative CT scan co-registered to the pre-op MRI and DTI for anatomic localization using previously described pipelines[72,73]. The CT scan and electrode contact positions were co-registered to a T_1 weighted anatomical MRI scan using SPM12 (https://fil.ion.ucl.ac.uk/spm/)[74] Freesurfer (http://surfer.nmr.mgh.harvard.edu/) was used to segment the T_1 weighted MRI

and the electrodes labeled according to the Destrieux atlas[75,76]. The final electrode contact localization for impedance analysis was performed with Lead DBS[73].

Epilepsy patient assistant (EPA). The electrophysiology data and patient reports were collected using epilepsy patient assistant (EPA), a custom software application running on a handheld computer enabling bidirectional communication between the implanted device and local and cloud computing resources. The EPA features include validated automated algorithms for continuous analysis of LFP data, control of electrical stimulation and impedance testing, LFP analysis and an interface for collecting patient interactions.[44,47]

Electrical Stimulation of ANT. The ANT stimulation electrodes pairs used for long-term ANT-DBS were selected by demonstrating the activation of Papez circuit, as evidenced by presence of a ~40 ms latency HPC evoked response[77] (see supplementary materials). Bipolar pairs were selected for chronic ANT-DBS to reduce stimulation artifacts and optimize HPC sensing for LPF seizure and IES detection (see supplementary data). Electrical brain stimulation of ANT was applied between bipolar electrode contact pairs in the ANT using continuous low frequency (2/7 Hz; 200us pulse width; up to 6 mA) or duty cycle (1 min on/ 5 min off) high frequency (145 Hz; 100 – 200 us pulse width; up to 5 mA).

Long-term sensing local field potentials: Four bipolar electrode pairs were selected for sensing based on ability to record seizures and IES. The four bipolar pairs can be selected from the 16 electrode contacts. The sampling rate of the LFP can be set at 250, 500, or 1000 Hz. Most of the LFP data was collected at 250 Hz because of significant increase in wireless data drops with higher 500 Hz and 1000 Hz sampling rates. (see supplementary materials)

Local Field Potential Analysis: The LFP analysis was performed using the EPA and cloud platform with AI computational infrastructure and visualization. Validated automated machine-learning algorithms were applied to the long-term LFP recordings to identify seizures, IES[34] and classify wake-sleep state (Awake, REM, and NREM)[45,46,49]. The algorithm pipeline identifies seizures, IES, brain impedance, and sleep-wake behavioral state for consecutive 30-second data segments. The algorithms and their performances were previously reported[34,45] (see supplementary materials). The sleep-wake classifications and seizure events are synchronized with patient reports for further offline analysis. Toolboxes and data for automated LFP analysis for detecting IES, seizures, and performing sleep-wake classification are freely available (https://github.com/bnelair/best_toolbox).

Seizure and IES detection: The IES and seizures are electrographic biomarkers of pathologic, epileptogenic brain tissue and are readily identified by human visual review of LFP recordings. We used a previously validated algorithm[34,48] for detecting IES transients from LFP recordings. The adaptive IES algorithm enables detecting IES in long term LFP data with changing background activity commonly encountered in prolonged recordings spanning week to months of time. Here the gold-standard training data was used to set a hypersensitive threshold for all participants (see supplementary materials).

The intracranial LFP associated with epileptic seizures exhibits characteristic temporal and spectral evolution over a wide frequency range. We previously described an accurate seizure detector developed using a convolutional neural network with long-short-term-memory (CNN-LSTM) utilizing Short Time Fourier Transform (STFT) of the LFP as the input[34]. The CNN-LSTM outputs a seizure probability for 10 second data segments. Gold-standard visually

reviewed seizures are used for training, validation, and pseudo-prospective testing. The seizure detection performance using the CNN-LSTM model was previously reported for participants M1- 4 and here is applied to all five participants using a hypersensitive threshold in order to ensure all seizures are detected for the analysis. We visually reviewed all candidate seizure events detected by the hypersensitive automated CNN-LSTM detector. The temporal distribution of seizures was determined by plotting the circular histogram of seizure onset times for all verified seizures across all participants.

Sleep-wake classification from continuous LFP recordings: Sleep-wake classification in ambulatory participants living in their natural home environment was performed using an individualized behavioral state classifier using LFP features. As described previously in humans and canines simultaneous LFP and gold standard sleep annotations (expert review by EKS) from polysomnography (PSG) were used to train the fully automated sleep-wake classifier[45,46]. A validated Naïve Bayes classifier using features extracted from the LFP was used for long-term tracking of sleep-wake behavioral state classification.

Statistical analysis: We employed a generalized linear mixed model (GLMM) to examine the impacts of different therapy periods (LF-DBS, HF-DBS) and behavioral states (awake/sleep) on monthly self-reported seizure rates, monthly confirmed electrographic seizure and hourly IES rates. The analysis was done via lmer package in R[78]. See the details on data used and fitted models in Supplementary materials.

Verbal Memory Assessment in Ambulatory subjects in natural home environment: The verbal memory task utilized was an established verbal memory paradigm[50,51,79]. The task was programmed on the epilepsy patient assistant (EPA) application (Figure 6A). The task was performed with the participant remotely at different times of the day during the week, at their preference. The ANT-DBS was turned off during the task. Investigators contacted the participant by phone and remotely activated the task on a tablet computer, recorded and documented the verbal responses. In this task, participants were presented with a list of twelve proper nouns with the goal of later recalling them. Participants were instructed to commit these individual words to memory as they appeared one by one on a handheld tablet computer screen. Each word was displayed for a duration of 1600 ms, followed by a randomly varying blank interval of 750–1000 ms between words.

Immediately after the presentation of the final word in each list (during the encoding phase), participants engaged in a 20 second distractor task consisting of solving arithmetic problems. Following the completion of the distractor task, participants were tasked with verbally recalling as many of the twelve words as they could from the previously presented list, in any order, within a 30-second time frame (recall phase). Each session encompassed 25 sets of this encoding-distractor-recall procedure. The stimulation was reactivated upon successful completion of the task.

Immediate Mood Assessments
Mood assessments were integrated into the Epilepsy Patient Assistant (EPA) application, which was programmed to randomly query participants for their responses. Participants were prompted on a randomly selected day and time (10AM-6PM; one-to-four times a week) to complete the Immediate Mood Scaler 12 (IMS)[54]. The IMS is an ecological momentary assessment of 12 questions (7-point Likert scale) evaluating anxiety and depression symptoms in the moment. (see supplementary materials)

Data Availability
The MRI, electrophysiology, and participant outcome data are available upon reasonable requests. A subset of awake, sleep, interictal and ictal continuous LFP recordings are available at the BNEL website.

Code/Software/Data availability.

All data and analysis code are available on reasonable request from the authors (https://github.com/bnelair/best_toolbox).
MATLAB and Python code for the analysis and plotting figures for the main manuscript and supplementary information is available at https://github.com/bnelair

The IMS was presented on the EPA tablet application through a licensing agreement with Posit Science (San Francisco, CA)

Acknowledgements

This work was supported by National Institutes of Health–National Institute of Neurological Disorders and Stroke Grants UH2&3 NS095495, R01 NS112144 and U24 NS113637; Defense Advanced Research Projects Agency Grant HR0011-20-2-0028. The implanted devices were donated by Medtronic as part of the National Institutes of Health Brain Initiative. V.K. and V.S. were partially supported by institutional support of CTU in Prague. We thank Cindy Nelson, and Starr Guzman from Mayo Clinic for patient coordination; Abbey Becker, Dave Linde, and Scott Stanslaski from Medtronic for providing engineering support for the RC+S^{TM} devices and OpenMind for providing community expertise and resources (https://openmind-consortium.github.io/).

* V.K., *F.M, and *V.S. contributed equally to this work. Unrelated to this research, G.A.W., B.H.B., J.V.G., and B.N.L are named inventors for intellectual property developed at Mayo Clinic and licensed to Cadence Neuroscience. G.A.W. has licensed intellectual property developed at Mayo Clinic to NeuroOne. Mayo Clinic has received research support and consulting fees on behalf of G.A.W., B.N.L., and B.H.B. from Cadence Neuroscience, UNEEG Medical, NeuroOne, Epiminder, Medtronic, and Philips Neuro. P.C. has received research grant support from Neuronetics, NeoSync, and Pfizer; grant in kind (equipment support) from Assurex, MagVenture, and Neuronetics; and served as a consultant for Engrail Therapeutics, Myriad Neuroscience, Procter & Gamble, and Sunovion. T.D. is a consultant for Synchron, is on the advisory board of Cortec Neuro, is a shareholder collaborator of Bioinduction, and a shareholder director of Amber Therapeutics. All the other authors declare no competing financial interests.

Correspondence should be addressed to Gregory A. Worrell at worrell.gregory@mayo.edu and Vaclav Kremen at kremen.vaclav@mayo.edu

References

1. Devinsky, O. *et al.* Epilepsy. *Nat. Rev. Dis. Primers* **4**, (2018).
2. Epilepsy: a public health imperative. https://www.who.int/publications-detail-redirect/epilepsy-a-public-health-imperative.
3. *US Committee on the Public Health Dimensions of the Epilepsies. Epilepsy Across the Spectrum: Promoting Health and Understanding*. (National Academies Press, 2012).
4. Spencer, D. D., Gerrard, J. L. & Zaveri, H. P. The roles of surgery and technology in understanding focal epilepsy and its comorbidities. *Lancet Neurol.* **17**, 373–382 (2018).
5. Lehnertz, K., Bröhl, T. & Wrede, R. von. Epileptic-network-based prediction and control of seizures in humans. *Neurobiol. Dis.* **181**, 106098 (2023).
6. Kwan, P., Schachter, S. C. & Brodie, M. J. Drug-resistant epilepsy. *N. Engl. J. Med.* **365**, 919–926 (2011).
7. Papez, J. W. A proposed mechanism of emotion. *Arch. Neurol. Psychiatry* **38**, 725 (1937).
8. MacLEAN, P. D. Psychosomatic disease and the visceral brain; recent developments bearing on the Papez theory of emotion. *Psychosom. Med.* **11**, 338–353 (1949).
9. Engel, J., Pedley, T. A., Aicardi, J., Dichter, M. A. & Moshé, S. *Epilepsy: a comprehensive textbook*. (Lippincott Williams & Wilkins, 2007).
10. Engel, J., Jr *et al.* Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. *JAMA* **307**, 922–930 (2012).
11. Wiebe, S., Blume, W. T., Girvin, J. P., Eliasziw, M. & Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. *N. Engl. J. Med.* **345**, 311–318 (2001).
12. Bell, M. L. *et al.* Epilepsy surgery outcomes in temporal lobe epilepsy with a normal MRI. *Epilepsia* **50**, 2053–2060 (2009).
13. Fisher, R. S. & Velasco, A. L. Electrical brain stimulation for epilepsy. *Nat. Rev. Neurol.* **10**, 261–270 (2014).
14. Fisher, R. *et al.* Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. *Epilepsia* **51**, 899–908 (2010).
15. Salanova, V. *et al.* The SANTÉ study at 10 years of follow-up: Effectiveness, safety, and sudden unexpected death in epilepsy. *Epilepsia* **62**, 1306–1317 (2021).
16. Mirski, M. A., Rossell, L. A., Terry, J. B. & Fisher, R. S. Anticonvulsant effect of anterior thalamic high frequency electrical stimulation in the rat. *Epilepsy Res.* **28**, 89–100 (1997).
17. Zhong, X.-L. *et al.* Low-frequency stimulation of bilateral anterior nucleus of thalamus inhibits amygdale-kindled seizures in rats. *Brain Res. Bull.* **86**, 422–427 (2011).
18. Jou, S.-B., Kao, I.-F., Yi, P.-L. & Chang, F.-C. Electrical stimulation of left anterior thalamic nucleus with high-frequency and low-intensity currents reduces the rate of pilocarpine-induced epilepsy in rats. *Seizure* **22**, 221–229 (2013).
19. Mirski, M. A. & Ferrendelli, J. A. Interruption of the mammillothalamic tract prevents seizures in guinea pigs. *Science* **226**, 72–74 (1984).
20. Aggleton, J. P. & O'Mara, S. M. The anterior thalamic nuclei: core components of a tripartite episodic memory system. *Nat. Rev. Neurosci.* **23**, 505–516 (2022).
21. Child, N. D. & Benarroch, E. E. Anterior nucleus of the thalamus: functional organization and clinical implications. *Neurology* **81**, 1869–1876 (2013).

22. Tröster, A. I., Meador, K. J., Irwin, C. P., Fisher, R. S. & SANTE Study Group. Memory and mood outcomes after anterior thalamic stimulation for refractory partial epilepsy. *Seizure* **45**, 133–141 (2017).
23. Voges, B. Effect of deep brain stimulation in epilepsy (DBS-E) on sleep quality and sleep structure; stimulation of the anterior nucleus thamalicus, ant, using the stimulatersystem nullactivanull by medtronic, USA. *Epilepsia* (2013).
24. Voges, B. R. *et al.* Deep brain stimulation of anterior nucleus thalami disrupts sleep in epilepsy patients. *Epilepsia* **56**, e99–e103 (2015).
25. Szabó, J. P., Fabó, D., Pető, N., Sákovics, A. & Bódizs, R. Role of anterior thalamic circuitry during sleep. *Epilepsy Res.* **186**, 106999 (2022).
26. Gregg, N. M. *et al.* Anterior nucleus of the thalamus seizure detection in ambulatory humans. *Epilepsia* **62**, e158–e164 (2021).
27. Osorio, I. The NeuroPace trial: Missing knowledge and insights. *Epilepsia* **55**, 1469–1470 (2014).
28. Morrell, M. J. In response: The RNS System multicenter randomized double-blinded controlled trial of responsive cortical stimulation for adjunctive treatment of intractable partial epilepsy: Knowledge and insights gained. *Epilepsia* **55**, 1470–1471 (2014).
29. Fisher, R. S. Deep brain stimulation of thalamus for epilepsy. *Neurobiol. Dis.* **179**, 106045 (2023).
30. Lundstrom, B. N. & Gregg, N. M. What should we expect for real-world outcomes of deep brain stimulation of the anterior nucleus of the thalamus for epilepsy? *Neurology* **100**, 845–846 (2023).
31. Elger, C. E. & Hoppe, C. Diagnostic challenges in epilepsy: seizure under-reporting and seizure detection. *Lancet Neurol.* **17**, 279–288 (2018).
32. Elger, C. E. Epilepsy: lost in translation. *Lancet neurology* vol. 13 862–863 (2014).
33. Cook, M. J. *et al.* Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. *Lancet Neurol.* **12**, 563–571 (2013).
34. Sladky, V. *et al.* Distributed brain co-processor for tracking spikes, seizures and behaviour during electrical brain stimulation. *Brain Commun.* **4**, fcac115 (2022).
35. Paschen, E. *et al.* Hippocampal low-frequency stimulation prevents seizure generation in a mouse model of mesial temporal lobe epilepsy. *Elife* **9**, (2020).
36. Couturier, N. H. & Durand, D. M. Comparison of fiber tract low frequency stimulation to focal and ANT stimulation in an acute rat model of focal cortical seizures. *Brain Stimul.* **13**, 499–506 (2020).
37. Kile, K. B., Tian, N. & Durand, D. M. Low frequency stimulation decreases seizure activity in a mutation model of epilepsy. *Epilepsia* **51**, 1745–1753 (2010).
38. Koubeissi, M. Z., Kahriman, E., Syed, T. U., Miller, J. & Durand, D. M. Low-frequency electrical stimulation of a fiber tract in temporal lobe epilepsy. *Ann. Neurol.* **74**, 223–231 (2013).
39. Mechanisms of hippocampal seizure suppression by low frequency electrical stimulation (LFS) of the fimbria-fornix-hippocampal commissures (FFHC) in rats. *Annals of Neurology* (2009).
40. Alcala-Zermeno, J. L. *et al.* Invasive neuromodulation for epilepsy: Comparison of multiple approaches from a single center. *Epilepsy Behav.* **137**, 108951 (2022).
41. Lundstrom, B. N., Brinkmann, B. H. & Worrell, G. A. Low frequency novel interictal EEG biomarker for localizing seizures and predicting outcomes. *Brain Commun.* **3**, fcab231 (2021).
42. Alcala-Zermeno, J. L., Starnes, K., Gregg, N. M., Worrell, G. & Lundstrom, B. N. Responsive neurostimulation with low-frequency stimulation. *Epilepsia* **64**, e16–e22 (2023).
43. Cukiert, A., Cukiert, C. M., Burattini, J. A., Mariani, P. P. & Bezerra, D. F. Seizure outcome after hippocampal deep brain stimulation in patients with refractory temporal lobe epilepsy: A prospective, controlled, randomized, double-blind study. *Epilepsia* **58**, 1728–1733 (2017).
44. Kremen, V. *et al.* Integrating brain implants with local and distributed computing devices: A next generation epilepsy management system. *IEEE J. Transl. Eng. Health Med.* **6**, 2500112 (2018).

45. Mivalt, F. *et al.* Electrical brain stimulation and continuous behavioral state tracking in ambulatory humans. *J. Neural Eng.* **19**, 016019 (2022).

46. Mivalt, F. *et al.* Automated sleep classification with chronic neural implants in freely behaving canines. *J. Neural Eng.* **20**, (2023).

47. Pal Attia, T. *et al.* Epilepsy personal assistant device-A mobile platform for brain state, dense behavioral and physiology tracking and controlling adaptive stimulation. *Front. Neurol.* **12**, 704170 (2021).

48. Janca, R. *et al.* Detection of interictal epileptiform discharges using signal envelope distribution modelling: application to epileptic and non-epileptic intracranial recordings. *Brain Topogr.* **28**, 172–183 (2015).

49. Kremen, V. *et al.* Behavioral state classification in epileptic brain using intracranial electrophysiology. *J. Neural Eng.* **14**, 026001 (2017).

50. Kucewicz, M. T. *et al.* Evidence for verbal memory enhancement with electrical brain stimulation in the lateral temporal cortex. *Brain* **141**, 971–978 (2018).

51. Kucewicz, M. T., Worrell, G. A. & Axmacher, N. Direct electrical brain stimulation of human memory: lessons learnt and future perspectives. *Brain* **146**, 2214–2226 (2023).

52. Ezzyat, Y. *et al.* Direct brain stimulation modulates encoding states and memory performance in humans. *Curr. Biol.* **27**, 1251–1258 (2017).

53. Ezzyat, Y. *et al.* Closed-loop stimulation of temporal cortex rescues functional networks and improves memory. *Nat. Commun.* **9**, (2018).

54. Nahum, M. *et al.* Immediate mood scaler: Tracking symptoms of depression and anxiety using a novel mobile mood scale. *JMIR MHealth UHealth* **5**, e44 (2017).

55. Sladky, V. *et al.* Integrated human-machine interface for closed-loop stimulation using implanted and wearable devices. in *2022 IEEE International Conference on Systems, Man, and Cybernetics (SMC)* (IEEE, 2022). doi:10.1109/smc53654.2022.9945203.

56. Worrell, G. & Gotman, J. High-frequency oscillations and other electrophysiological biomarkers of epilepsy: clinical studies. *Biomark. Med.* **5**, 557–566 (2011).

57. Engel, J., Jr. Biomarkers in epilepsy: introduction. *Biomark. Med.* **5**, 537–544 (2011).

58. Kleen, J. K. *et al.* Hippocampal interictal epileptiform activity disrupts cognition in humans. *Neurology* **81**, 18–24 (2013).

59. Horak, P. C. *et al.* Interictal epileptiform discharges impair word recall in multiple brain areas. *Epilepsia* **58**, 373–380 (2017).

60. Camarillo-Rodriguez, L. *et al.* Temporal lobe interictal spikes disrupt encoding and retrieval of verbal memory: A subregion analysis. *Epilepsia* **63**, 2325–2337 (2022).

61. Matsumoto, J. Y. *et al.* Network oscillations modulate interictal epileptiform spike rate during human memory. *Brain* **136**, 2444–2456 (2013).

62. Peter-Derex, L. *et al.* Sleep disruption in epilepsy: Ictal and interictal epileptic activity matter. *Ann. Neurol.* **88**, 907–920 (2020).

63. Bower, M. R. *et al.* Evidence for consolidation of neuronal assemblies after seizures in humans. *J. Neurosci.* **35**, 999–1010 (2015).

64. Bower, M. R. *et al.* Reactivation of seizure-related changes to interictal spike shape and synchrony during postseizure sleep in patients. *Epilepsia* **58**, 94–104 (2017).

65. Goddard, G. V. Development of epileptic seizures through brain stimulation at low intensity. *Nature* **214**, 1020–1021 (1967).

66. Karoly, P. J. *et al.* Cycles in epilepsy. *Nat. Rev. Neurol.* **17**, 267–284 (2021).

67. Balzekas, I. *et al.* Invasive electrophysiology for circuit discovery and study of comorbid psychiatric disorders in patients with epilepsy: Challenges, opportunities, and novel technologies. *Front. Hum. Neurosci.* **15**, 702605 (2021).

68. Contreras Ramirez, V., Vaddiparti, A. & Blumenfeld, H. Testing awareness in focal seizures: Clinical practice and interpretation of current guidelines. *Ann. Clin. Transl. Neurol.* **9**, 762–765 (2022).

69. Touloumes, G. *et al.* Human bedside evaluation versus automatic responsiveness testing in epilepsy (ARTiE). *Epilepsia* **57**, e28-32 (2016).
70. Stanslaski, S. *et al.* A chronically implantable neural coprocessor for investigating the treatment of neurological disorders. *IEEE Trans. Biomed. Circuits Syst.* **12**, 1230–1245 (2018).
71. Gilron, R. *et al.* Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson's disease. *Nat. Biotechnol.* **39**, 1078–1085 (2021).
72. Hermes, D., Miller, K. J., Noordmans, H. J., Vansteensel, M. J. & Ramsey, N. F. Automated electrocorticographic electrode localization on individually rendered brain surfaces. *J. Neurosci. Methods* **185**, 293–298 (2010).
73. Horn, A. *et al.* Lead-DBS v2: Towards a comprehensive pipeline for deep brain stimulation imaging. *Neuroimage* **184**, 293–316 (2019).
74. Penny, W. D., Friston, K. J., Ashburner, J. T., Kiebel, S. J. & Nichols, T. E. *Statistical Parametric Mapping: The Analysis of Functional Brain Images*. (Elsevier, 2011).
75. Fischl, B. *et al.* Automatically parcellating the human cerebral cortex. *Cereb. Cortex* **14**, 11–22 (2004).
76. Destrieux, C., Fischl, B., Dale, A. & Halgren, E. Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. *Neuroimage* **53**, 1–15 (2010).
77. Wang, Y.-C. *et al.* Probing circuit of Papez with stimulation of anterior nucleus of the thalamus and hippocampal evoked potentials. *Epilepsy Res.* **159**, 106248 (2020).
78. R Core Team. R: A Language and Environment for Statistical Computing. Preprint at http://www.R-project.org/ (2013).
79. Kahana, M. J. *Foundations of human memory*. (Oxford University Press, 2012).

Tables

Table 1: Patient Demographics and Clinical Information.

Participant	Age, Hand(L/R), Gender (M/F), Onset age & DRE (yrs)	Risk Factor (RF) Medical Hx: Surgical Hx:	TL Seizure Types	ASM 1) Current 2) Previous	EEG 1) Scalp 2) Intracranial	MRI PET SPECT
M1	55-60 y.o.; RF; Onset 5-10. y.o. DRE: 36 yrs EMU: scalp EEG & sEEG.	RF: TBI Medical: Anxiety & Depression Surgical: None	FAS, FIAS, Rare FBTC	1) GBP, CZP 2) LEV, OXC PHT, CBZ	1) B.IES & Szs. 2) B.HPC IES & Szs	MRI: Normal PET: N/A SPECT: N/A
M2	20-25 y.o.; RF; Onset 5-10 y.o. DRE 3 yrs. EMU: scalp EEG only	RF: None Medical: Anxiety, Depression, DM. Surgical: L.ATL	FAS, FIAS, Rare FBTC	1) LCM, CLZ, 2) LEV, PHT, CBZ, OXC	1) B. IES & Sz. 2) N/A	MRI: L.ATL PET: N/A SPECT: N/A
M3	40-45 y.o.; RF; Onset 30-35 y.o. DRE 10 yrs. EMU: scalp EEG & iEEG	RF: None Medical: Anxiety, Depression, GAD-65 positive serum/CSF Surgical: VNS	FAS, FIAS, Rare FBTC	1) CLZ, LEV, CNB 2) LZP, CBZ, PHT, TPX, LCM, CBD	1) B.IES & Szs. 2) B.HPC IES & Szs	MRI: Normal PET: N/A SPECT: N/A
M4	35-40 y.o.; RF; Onset 0-5 y.o. DRE 7 yrs. EMU: scalp EEG & sEEG	RF: None Medical: Anxiety, Depression, GAD-65 positive serum/CSF Surgical: None	FAS, FIAS, Rare FBTC	1) OXC, LEV 2) LCM, CBZ, PHT, LGT	1) B.IES & Szs. 2) B. HPC IES & Szs	MRI: Normal PET: N/A SPECT: N/A
M5	30-35 y.o. RM; Onset 20-25 y.o. DRE 5 yrs. EMU: scalp EEG only	RF: TBI & Family history of epilepsy Medical: Anxiety, Depression Surgical: None	FAS, FIAS, Rare FBTC	1) LCM, VPA 2) LEV, LGT, PHT, CBZ	1) B.IES & Szs. 2) N/A	MRI: L. HPC atrophy & incr. T2 signal PET: N/A SPECT: N/A

Table 1: Patient Demographics: The patients had mesial temporal lobe epilepsy and HPC seizures. All patients had bilateral independent IES and seizures in the Phase-1 evaluation and M1, M3 and M4 had invasive stereo-EEG (sEEG) evaluations and had bilateral independent IES and seizures.

Abbreviations: Electroencephalography (EEG). Drug resistant epilepsy (DRE). Male/Female (M/F). Right/Left (R/L). Bilateral (B). Deep Brain Electrical Stimulation (DBS). Traumatic brain injury (TBI). Vagus Nerve Stimulation (VNS). Anterior temporal lobectomy (ATL), Temporal lobe (TL), Focal aware seizures (FAS), Focal impaired awareness seizures (FIAS). Focal to bilateral tonic-clonic (FBTC). Gabapentin (GBP), Benzodiazepine (BZD), Levetiracetam (LEV), Oxcarbazepine (OXC), Phenytoin (PHT), Carbamazepine (CBZ), Lacosamide (VPT), Valproic Acid (VPA). Interictal epileptiform spikes (IES), Seizures (Sz), increased (incr.), Hippocampus (HPC).

Table 2: Participant Device Related Adverse Events & Outcomes.

		AE	QOLiE	BDI	LSSS	BNT	CFL	RAVLT	RAVLT (DR)	VPA (IR)	VPA (DR)	VR (IR)	VR (DR)
M1	Baseline	0	50.1	10	65	59	37	47	26	5	7	9	6
	Low Frequency	0	34.8	26	58	52	32	36	19	4	4	7	6
	High Frequency	1	30.1	18	68	56	35	36	15	4	4	7	5
M2	Baseline	0	49.2	27	48	41	36	31	23	7	5	8	5
	Low Frequency	1	42.7	38	49	40	32	35	27	5	5	9	9
	High Frequency	0	64.8	35	40	45	39	35	20	7	7	12	9
M3	Baseline	0	41.3	18	55	50	32	43	44	11	9	6	8
	Low Frequency	0	44.5	21	60	48	25	44	32	5*	4*	7	7
	High Frequency	0	41.6	19	38	51	24	52	40	6*	5	10	7
M4	Baseline	0	46.1	16	80	51	45	21	18	8	4	10	6
	Low Frequency	0	66.7	3	58	53	39	13	18	8	5	10	6
	High Frequency	1	53.4	9	53	48	30	5*	11	3*	2	10	7
M5	Baseline	1	60.6	2	45	56	36	47	44	11	9	10	9
	Low Frequency	0	53.5	8	43	58	37	52	44	10	11	9	10
	High Frequency	0	46.6	13	35	56	43	56	44	11	12	9	10

Table 2: Participant Device Related Adverse Events & Outcomes
Participants were monitored during baseline and while receiving continuous low frequency or duty cycle high frequency ANT-DBS (average 99.2 +- 43 weeks). There were 4 device related adverse events reported to the FDA. Participants M1 and M4 developed worsening dysphoria, anxiety and sleep disruption with continuous high frequency ANT-DBS. The symptoms resolved after change to duty cycle (1 minute on & 5 minute off) ANT-DBS parameters. M2 inadvertently disabled therapy using the EPA application. A subsequent EPA reversion corrected this potential operator mistake, and the cloud dashboard more clearly displayed the therapy status to identify clinical team. At surgery for M5 the device lead could not be completely seated into the connector leaving on 3 recording right HPC contacts. There were no infections, intracranial hemorrhages, status epilepticus, or deaths. Participant M4 was hospitalized for new onset functional event. Participant M5 had 3 overnight hospitalizations with recurrent seizures like his baseline. All participants had repeated neuropsychological testing (NP) during the trial. Testing took place during scheduled in-person office visits. All participants had NP at baseline and during low frequency ANT-DBS and high frequency duty cycle ANT-DBS. Participant M3 there was a decrease in VPA immediate and delayed recall compared to baseline. For M5 both RAVLT and VPA immediate was reduced during high frequency ANT-DBS.

Abbreviations: Anterior nucleus of the thalamus (ANT); Boston Naming Test (BNT; Raw Total of 60); Letter Fluency Raw (CFL); Deep brain stimulation (DBS); Hippocampus (HPC); Rey Auditory Verbal Learning Test (RAVLT); Verbal Paired Associates (VPA); Visual Reproduction (VR). Delayed Recall (DR); Immediate Recall (IR); Total scores (T) have a mean of 50 and standard deviation of 10. Scaled scores (ss) have a mean of 10 and standard deviation of 3. *Declined From Baseline

Table 3: BrainRISE Platform Performance

Participant	Weeks Monitored	Daily LFP data (hr.)	Total Reported seizures	EPA Reported seizures/month
M1	168	15.16 ± 3.03	144	3.43 ± 2.28
M2	92	5.64 ± 3.58	151	6.57 ± 4.51
M3	80	17.09 ± 2.11	429	21.45 ± 7.27
M4	104	16.97 ± 2.29	59	2.27 ± 0.78
M5	52	13.92 ± 3.22	30	2.31 ± 3.01
Mean	*99.2±43.0*	*13.76 ± 4.73*	*162±158*	*7.2 ± 8.1*

Table 3: BrainRISE Platform Performance
Participants were monitored over multiple months while receiving ANT-DBS (average 99.2 +- 43 weeks). Daily wireless data transmitted varied considerably across participants and reflects current technology limitation, and challenges with managing multiple rechargeable wireless streaming devices. Participants reported their seizures using the EPA application.
Abbreviations: Epilepsy patient assistant application (EPA). Anterior nucleus of the thalamus (ANT). Deep brain stimulation (DBS).

Table 4: Lateralization of Epileptiform Activity.

Lateralization of interictal epileptiform spikes (IES) and seizures (Sz)				
Participant	#IES L>R (**p<0.001 all participants**)		Seizure L>R (**p<0.001 M1,2,4,5**)	
	L. AMG-HPC	R. AMG-HPC	L. AMG-HPC	R. AMG-HPC
M1	1,928 ± 1,061	199 ± 276	690	75
M2	1,830 ± 2,247	1603 ± 929	3,730	18
M3	1,859 ± 859	969 ± 567	171	269
M4	265 ± 246	37 ± 28	45	0
M5	1,273 ± 482	725 ± 548	179	48

Table 4: Lateralization of Epileptiform Activity. Comparison of interictal epileptiform spike rates (IES) and number of seizure onsets in post-implant ambulatory monitoring phase of the study. All participants had seizures that started unilaterally and then propagated to contralateral AMG - HPC. All participants had bilateral independent IES, and all but M4 had bilateral independent seizures recorded. In all participants the IES activity was increased in left compared to right AMG-HPC. Similarly, M1, M2, M4 and M5 had more seizures originating from the left AMG and HPC. Note that M4 did not have seizures from right HPC during tracking in her natural home environment and medication regime in contrast to the hospital epilepsy monitoring evaluation shown in Table 1.

Table 5: Sleep characteristics.

Sleep	M1	M2	M3	M4	M5	Overall
Onset [hr:min]	12:27 am ± 01:07	02:18 am ± 02:22	10:43 am ± 00:39	10:42 pm ± 00:37	01:07 am ± 02:07	11:59 pm ± 01:56
Offset [hr:min]	08:55 am ± 01:01	11:33 am ± 03:01	07:39 am ± 00:31	08:06 am ± 00:51	08:29 am ± 02:59	08:35 am ± -2:07
Sleep Duration [hr:min]	08:19 ± 01:28	08:49 ± 03:04	08:49 ± 00:40	09:28 ± 00:52	07:07 ± 02:01	08:33 ± 01:56
NREM Duration [hr:min]	05:39 ± 00:57	07:01 ± 02:21	06:29 ± 00:37	06:16 ± 00:54	03:06 ± 00:45	05:41 ± 01:51
REM Duration [hr:min]	01:58 ± 00:29	01:09 ± 00:40	02:09 ± 00:27	02:41 ± 00:52	02:35 ± 01:06	02:10 ± 00:56
Awake Duration [hr:mins]	00:42 ± 00:40	00:39 ± 00:33	00:11 ± 00:12	00:30 ± 00:39	01:26 ± 01:05	00:41 ± 00:48
Cycles	5.13 ± 2.43	2.78 ± 2.47	3.90 ± 2.55	3.67 ± 2.07	5.00 ± 2.00	4.04 ± 2.50
NREM Epoch Duration [mins]	18.46 ± 29.36	28.16 ± 40.59	20.53 ± 33.04	16.89 ± 8.71	23.20 ± 27.02	19.93 ± 31.91

Table 5: Sleep Characteristics. The participant specific sleep-wake classifier was trained in the epilepsy monitoring unit using gold-standard scalp polysomnography and streaming local field potentials from hippocampus (see supplementary materials). The average sleep onset times, offset times, sleep duration, total non-rapid eye movement (NREM) duration, total rapid eye movement (REM) duration, total awake duration, number of NREM-REM cycles, and average duration of NREM epochs were tabulated for all participants. The average sleep duration for all 5 participants was 08:33 ± (01:56) with 4:04 ± 2.50 NREM-REM cycles. The average NREM epoch duration was 19.93 ± 31.91 minutes. The table highlights the variability across and within individual participants.

Abbreviations: rapid eye movement (REM), non-rapid eye movement (NREM).

Figures

Figure 1. Monitoring brain electrophysiology and behavior in ambulatory humans living in their home environment. **A)** Safety and feasibility protocol for the 4-lead limbic network implant with investigational neural sensing-stimulation Medtronic Summit RC+S™ (see supplementary materials). **B)** The neural stimulation and sensing implant device enables wireless streaming of brain local field potentials (LFP) to a tablet computer running a custom epilepsy patient assistant application (EPA). The EPA application orchestrates integration and synchronization of multiple devices and provides a system for bidirectional communication between devices, participants and the clinical team. In participants with mesial temporal lobe epilepsy (mTLE), limbic circuit network nodes were implanted with 4-contact leads targeting bilateral amygdala-hippocampus (HPC) and anterior nucleus of thalamus (ANT) (inset view). The sensing-stimulation lead extensions were tunneled under the skin to the RC+S™ device implanted in a surgically created pocket over the left pectoralis muscle. The RC+S™ device supports bidirectional wireless communications and streaming of 4-bipolar LFP channels to a small handheld tablet computer via a relay telemetry device typically worn by the individual. Bidirectional wireless communication between the implantable neural sensing-stimulation device, tablet computer, and cloud environment enables analysis of synchronized brain electrophysiology, patient inputs, and behavior. Automatically or manually triggered behavioral surveys run on the tablet computer (see supplementary materials). **C)** Representative LFP recorded from epileptogenic HPC. Automated machine learning detectors were deployed to capture pathological interictal epileptiform spikes (IES) and electrographic seizure discharges (Sz). Circled insets highlight automated IES and Sz detections in an ambulatory participant (M1) in their natural home environment. **D)** *Top:* Representative LFP spectral power recorded from HPC. The characteristic spectral changes associated with awake and sleep behavioral states are visually evident with increased Delta frequency (1 – 4 Hz) activity in sleep and increased Beta frequency (13 – 20 Hz) activity in wakefulness. Simultaneous scalp polysomnography and LFP recordings were used to develop an automated LFP based behavioral state classifier: awake (W), rapid eye movement (REM) sleep, and non-REM sleep. *Bottom:* Hypnogram generated from continuous LFP recordings using a Naïve Bayesian Classifier. **E)** Verbal memory sessions were performed in participants' home environment. Verbal memory sessions consist of an average of 15 trials of a verbal memory task comprised on encoding, distraction and recall of 12 proper nouns.

Figure 2: Anterior Nucleus of Thalamus Deep Brain Stimulation (ANT-DBS) and Seizures.
Patients reported their seizures using the epilepsy patient application (EPA) running on a handheld tablet computer during baseline prior to surgery (PREIMP: 3 months prior to implant), after device implant before starting ANT-DBS (NOSTIM: 4 weeks), and during continuous low-frequency 2 & 7 Hz ANT-DBS (LF-DBS) or duty cycle (1 minute on, 5 minutes off) high-frequency 145 Hz ANT-DBS (HF-DBS). **A)** *Top:* Scatter plot of individual monthly reported seizures and the mean over all months (dashed lines). *Bottom:* Both LF and HF ANT-DBS reduced seizures compared to baseline by 50% at a group level (GLMM, p < 0.05), and in four of five individuals. The patient (M4) with an increase in reported seizures after implant was receiving high-dose diazepam therapy that had to be discontinued because of mood decline and fatigue on week 5 after implant, which was associated with an increase in seizures. **B)** Patient reported seizures versus detected electrographic seizures captured with continuous hippocampal local field potential (LFP) streaming. Notably, some participants reported seizures (e.g. M3) that were not associated with an electrographic LFP correlate and some (M1&M5) had more electrographic LFP seizures than they reported.
Abbreviations: Anterior Nucleus of Thalamus Deep Brain Stimulation (ANT-DBS), Epilepsy Patient Assistant (EPA), High frequency duty cycle ANT-DBS (HF-DBS), General linear mixed model (GLMM) Local field potentials (LFP), Low frequency continuous ANT-DBS (LF-DBS), no stimulation period (NOSTIM), pre-implant baseline (PREIMP), Seizure (Sz). *(See supplementary materials)*

Figure 3. Circadian Patterns of Seizures and Interictal Epileptiform Spikes.
Epileptogenic human hippocampus (HPC) generates spontaneous seizures (Sz) and interictal epileptiform spikes (IES) that are modulated by awake-sleep behavioral states. The habitual Sz primarily occurred diurnally during wakefulness with a complex, patient specific, distribution of increased occurrence. The Sz rarely occurred during sleep compared to wakefulness. Conversely, IES were increased during sleep, particularly in non-rapid eye movement (NREM). **A)** Circular 24-hr histograms of Sz occurrence for each participant show detected electrographic seizures (red-solid), IES rates (blue-dashed) and sleep-wake classification (gray-filled) using validated algorithms applied to continuous local field potentials (LFP). Each individual's Sz primarily occur during wakefulness with patient specific distributions approximating unimodal (M4 & M5) or bimodal (M1,2,3) distributions. **B)** Aggregated Sz and IES across all patients show the differential behavioral state modulation of epileptiform activity, IES and Sz. **C)** The seizures are more common in daytime during wakefulness (p<0.0001) and **D)** IES rates are higher in sleep (p < 0.0001). GLMM group estimated fit with confidence intervals in solid black.
Abbreviations: General linear mixed model (GLMM), hippocampus (HPC), Interictal epileptiform spikes (IES), local field potentials (LFP). non-rapid eye movement (NREM), Seizure (Sz).

Figure 4: Electrographic seizures and interictal epileptiform spikes (IES) recorded from hippocampus (HPC) during Anterior Nucleus Thalamus Deep Brain Stimulation.
A validated automated seizure and IES detector was used to catalog electrographic seizures and IES transients from streaming hippocampal (HPC) local field potential (LFP) recordings (see also Figure 1B) over multiple months in participants with mTLE. Here we compare continuous low frequency (LF-DBS) and duty cycle high frequency (HF-DBS) stimulation paradigms. Participant M2 did not have adequate data rates during HF-DBS and was omitted from the GLMM seizure analysis (see supplementary materials). GLMM group estimated fit with confidence intervals in solid black. **A)** The electrographic seizures during wakefulness recorded from bilateral HPC were reduced during continuous LF-DBS compared to duty cycle HF-DBS. **B)** The IES rates during wakefulness were decreased during LF-DBS compared to HF-DBS for all 5 patients. **C)** Electrographic seizures during sleep recorded from bilateral HPC are infrequent and similar between continuous LF-DBS and duty cycle HF-DBS. **D)** The IES rates (showing only IES from left HPC) during sleep were decreased during LF-DBS compared to HF-DBS (p < 0.01).
Abbreviations: General linear mixed model (GLMM), hippocampus (HPC), Interictal epileptiform spikes (IES), local field potentials (LFP). Seizure (Sz).

Figure 5: Effect of Anterior Nucleus of Thalamus Deep Brain Stimulation (ANT-DBS) on Sleep. The impact of ANT-DBS neuromodulation on sleep was investigated using long-term behavioral state classifications (awake-sleep) from a validated Naïve Bayesian Classifier applied to local field potential recordings from ambulatory participants living in their home environments. The wake-sleep classifier used LFP to label behavioral states as Wakefulness (W), rapid eye movement sleep (REM) and non-REM sleep (NREM). **A)** ANT-DBS neuromodulation with continuous LF-DBS or duty cycle HF-DBS did not impact total sleep duration (sleep onset – sleep offset). **B)** The time spent awake after sleep onset (WASO) was reduced by LF-DBS compared to baseline without stimulation (p < 0.05). Duty cycle HF-DBS increased WASO compared to both baseline (p < 0.01) and LF-DBS (p < 0.0001) **C)** Influence of ANT-DBS on time spent in NREM+REM sleep. The overall time spent in NREM and REM was reduced during HF-DBS compared to no stimulation baseline and LF-DBS. The total NREM-REM time in sleep with continuous LF-DBS neuromodulation was indistinguishable from no stimulation baseline and longer than duty-cycle HF-DBS (p < 0.05).

Abbreviations: Anterior nucleus thalamus deep brain stimulation (ANT-DBS), hippocampus (HPC), Interictal epileptiform spikes (IES), local field potentials (LFP), Seizure (Sz), wakefulness after sleep onset (WASO), rapid eye movement sleep (REM) and non-REM (NREM).

Figure 6: Effect of ANT-DBS on Verbal Memory Performance. The impact of continuous LF-DBS and duty cycle HF-DBS on verbal memory was investigated using a simple word encoding-recall task performed remotely by participants living in their home environment. **A)** Patients used the epilepsy patient assistant (EPA) application running on their tablet computer to perform a validated word-recall task. The task was performed with the participant at different times of the day according to individual preference. Investigators contacted the research participant by phone for the remote verbal memory task. The investigator remotely activated the task on the participant's tablet computer. The completed task consisted of an average of 15 trials performed using lists of 12 words. A proper noun is randomly selected from a large database and presented on the screen for 10 seconds. After presentation of the 12 nouns a simple math distractor is presented that the patient performs simple addition. Subsequently there is a period of free recall where the patient recalls as many words, in any order, as possible from the prior encoding list. **B)** Verbal memory scores for free recall were better during periods the participants were receiving LF-DBS compared to HF-DBS. Note, the ANT-DBS is off while the task is being performed.

Abbreviations: Anterior nucleus thalamus deep brain stimulation (ANT-DBS). Epilepsy patient assistant application (EPA).